The Antiparasitic Market is expected to register a CAGR of 5.7% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The Antiparasitic Market report covers analysis by Drug Class (Anthelmintics, Antiprotozoals, Others); Disease Indication (Giardiasis, Trichuriasis, Filariasis, Neurocysticercosis, Hydatid disease, Pinworm disease, Cysticercosis, Ascariasis, Others); Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies, Others), and Geography (North America, Europe, Asia Pacific, and South and Central America). The global analysis is further broken-down at regional level and major countries. The report Offers the Value in US$ for the above analysis and segments.
Purpose of the ReportThe report Antiparasitic Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Antiparasitic Market Segmentation
Drug Class- Anthelmintics
- Antiprotozoals
- Giardiasis
- Trichuriasis
- Filariasis
- Neurocysticercosis
- Hydatid disease
- Pinworm disease
- Cysticercosis
- Ascariasis
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
Strategic Insights
Antiparasitic Market Growth Drivers- Increasing Incidence of Parasitic Infections: The continuously growing prevalence of parasitic infections in the world is a major factor contributing to the antiparasitic market, especially in tropical and subtropical countries. Such diseases include malaria, leishmaniasis, schistosomiasis, and hookworm infestations, among other parasitic diseases affecting millions of people worldwide. Besides, the migration of the population from the endemic into the non-endemic area is leading to an increased spread of parasitic infections, thus increasing demand for treatment options.
- Veterinary Expanding Market: Apart from human health, antiparasitic drugs have massive applications in veterinary medicine, which manages parasitic infestations among animals. This is attributed to the increasing global demand for animal products and pets, hence increasing demand for effective parasitic control in animals. This presents a growing market for veterinary antiparasitic drugs, driving overall market growth by making up for additional revenues for manufacturers.
- Resistance to Existing Antiparasitic Drugs: The development of resistance by parasites against conventional antiparasitic drugs necessitates the discovery and development of new drugs. Parasites resistant to older treatments create the need to produce new and more potent drugs, hence creating continuous demand for newer and more efficient antiparasitics. This presents a big opportunity for research-oriented pharmaceuticals.
- Focus on Combination Therapies: There has been an upward trend in the development of combination therapies in the antiparasitic market. This could be to enhance effectiveness and reduce the risk of resistance, whereby more than one stage of the parasite lifecycle or mechanisms of action may be targeted simultaneously with multiple drugs. Combination therapies have become a fast-growing interest since the outcome is improved from monotherapy.
- Shift to Biologics and Immunotherapies: Accompanied by advancements in biotechnology, there is a fast-growing interest in biologics and immunotherapies to address parasitic infections. Thus, vaccines and monoclonal antibodies have increasingly been pursued both as possible therapies to prevent parasite infection or for enhancing the immune response of a host to kill the parasites. This will spur a new evolution in the treatment landscape toward targeted long-lasting protection for parasitic diseases.
- Rising Focus on Vector-Borne Diseases: Vector-borne diseases, such as malaria, dengue fever, and Zika virus, prevail in a great part of the world. Accelerated control measures have increased the need for innovative antiparasitic drugs targeting parasites carried by vectors. This has also motivated research into new mosquito repellents and treatments aimed at the vectors themselves, including mosquitoes. Such a trend is pushing the market toward innovative solutions for the management and prevention of these diseases.
- Government Initiatives and Funding: Governments of various countries, along with international organizations like the WHO and the Global Fund, are putting more emphasis on the fight against parasitic diseases, especially in low-income countries. New treatments and vaccines, coupled with funding for mass drug administration programs, are likely to create significant opportunities for the market players. Companies operating in the development of new antiparasitic drugs may benefit from grants, subsidies, and partnerships with these organizations.
- Investment in the R&D for New Antiparasitic Drugs: The growing resistance of parasites to drugs has increased the demand for new therapies. Therefore, pharmaceutical companies and research institutions are investing in the development of new antiparasitic drugs effective even against drug-resistant strains. The possibility of developing new, more efficient, and safer drugs offers highly lucrative opportunities for market share capture and unmet medical needs fulfillment.
- Strategic Partnerships and Collaborations: The development of antiparasitic drugs has to be done in collaboration between pharmaceutical companies, research institutions, and NGOs. Partnerships facilitate resource sharing, collaboration in clinical trials, and distribution of drugs in resource-poor regions of the world. These partnerships create new market opportunities and hasten the development and distribution of new antiparasitic therapies.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Antiparasitic Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Antiparasitic Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The major factors driving the Antiparasitic Market are Increasing Incidence of Parasitic Infections, Veterinary Expanding Market, and Resistance to Existing Antiparasitic Drugs
The key future trends of the market are Focus on Combination Therapies, Shift to Biologics and Immunotherapies, and Rising Focus on Vector-Borne Diseases
The leading players operating in the Antiparasitic Market include Ipca Laboratories Ltd., Zydus Cadila, Merck KGaA, Pfizer, GlaxoSmithKline Plc., Cipla Ltd, Ranbaxy Laboratories, Novartis AG, Alvizia Health Care.
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on the request are an additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Antiparasitic Market - By Drug Class
1.3.2 Antiparasitic Market - By Disease Indication
1.3.3 Antiparasitic Market - By Distribution Channel
1.3.4 Antiparasitic Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ANTIPARASITIC MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ANTIPARASITIC MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ANTIPARASITIC MARKET - GLOBAL MARKET ANALYSIS
6.1. ANTIPARASITIC - GLOBAL MARKET OVERVIEW
6.2. ANTIPARASITIC - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. ANTIPARASITIC MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. ANTHELMINTICS
7.3.1. Overview
7.3.2. Anthelmintics Market Forecast and Analysis
7.4. ANTIPROTOZOALS
7.4.1. Overview
7.4.2. Antiprotozoals Market Forecast and Analysis
7.5. OTHERS
7.5.1. Overview
7.5.2. Others Market Forecast and Analysis
8. ANTIPARASITIC MARKET - REVENUE AND FORECASTS TO 2028 - DISEASE INDICATION
8.1. OVERVIEW
8.2. DISEASE INDICATION MARKET FORECASTS AND ANALYSIS
8.3. GIARDIASIS
8.3.1. Overview
8.3.2. Giardiasis Market Forecast and Analysis
8.4. TRICHURIASIS
8.4.1. Overview
8.4.2. Trichuriasis Market Forecast and Analysis
8.5. FILARIASIS
8.5.1. Overview
8.5.2. Filariasis Market Forecast and Analysis
8.6. NEUROCYSTICERCOSIS
8.6.1. Overview
8.6.2. Neurocysticercosis Market Forecast and Analysis
8.7. HYDATID DISEASE
8.7.1. Overview
8.7.2. Hydatid disease Market Forecast and Analysis
8.8. PINWORM DISEASE
8.8.1. Overview
8.8.2. Pinworm disease Market Forecast and Analysis
8.9. CYSTICERCOSIS
8.9.1. Overview
8.9.2. Cysticercosis Market Forecast and Analysis
8.10. ASCARIASIS
8.10.1. Overview
8.10.2. Ascariasis Market Forecast and Analysis
8.11. OTHERS
8.11.1. Overview
8.11.2. Others Market Forecast and Analysis
9. ANTIPARASITIC MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL PHARMACIES
9.3.1. Overview
9.3.2. Hospital pharmacies Market Forecast and Analysis
9.4. RETAIL PHARMACIES
9.4.1. Overview
9.4.2. Retail pharmacies Market Forecast and Analysis
9.5. ONLINE PHARMACIES
9.5.1. Overview
9.5.2. Online pharmacies Market Forecast and Analysis
9.6. OTHERS
9.6.1. Overview
9.6.2. Others Market Forecast and Analysis
10. ANTIPARASITIC MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Antiparasitic Market Overview
10.1.2 North America Antiparasitic Market Forecasts and Analysis
10.1.3 North America Antiparasitic Market Forecasts and Analysis - By Drug Class
10.1.4 North America Antiparasitic Market Forecasts and Analysis - By Disease Indication
10.1.5 North America Antiparasitic Market Forecasts and Analysis - By Distribution Channel
10.1.6 North America Antiparasitic Market Forecasts and Analysis - By Countries
10.1.6.1 United States Antiparasitic Market
10.1.6.1.1 United States Antiparasitic Market by Drug Class
10.1.6.1.2 United States Antiparasitic Market by Disease Indication
10.1.6.1.3 United States Antiparasitic Market by Distribution Channel
10.1.6.2 Canada Antiparasitic Market
10.1.6.2.1 Canada Antiparasitic Market by Drug Class
10.1.6.2.2 Canada Antiparasitic Market by Disease Indication
10.1.6.2.3 Canada Antiparasitic Market by Distribution Channel
10.1.6.3 Mexico Antiparasitic Market
10.1.6.3.1 Mexico Antiparasitic Market by Drug Class
10.1.6.3.2 Mexico Antiparasitic Market by Disease Indication
10.1.6.3.3 Mexico Antiparasitic Market by Distribution Channel
10.2. EUROPE
10.2.1 Europe Antiparasitic Market Overview
10.2.2 Europe Antiparasitic Market Forecasts and Analysis
10.2.3 Europe Antiparasitic Market Forecasts and Analysis - By Drug Class
10.2.4 Europe Antiparasitic Market Forecasts and Analysis - By Disease Indication
10.2.5 Europe Antiparasitic Market Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Antiparasitic Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Antiparasitic Market
10.2.6.1.1 Germany Antiparasitic Market by Drug Class
10.2.6.1.2 Germany Antiparasitic Market by Disease Indication
10.2.6.1.3 Germany Antiparasitic Market by Distribution Channel
10.2.6.2 France Antiparasitic Market
10.2.6.2.1 France Antiparasitic Market by Drug Class
10.2.6.2.2 France Antiparasitic Market by Disease Indication
10.2.6.2.3 France Antiparasitic Market by Distribution Channel
10.2.6.3 Italy Antiparasitic Market
10.2.6.3.1 Italy Antiparasitic Market by Drug Class
10.2.6.3.2 Italy Antiparasitic Market by Disease Indication
10.2.6.3.3 Italy Antiparasitic Market by Distribution Channel
10.2.6.4 Spain Antiparasitic Market
10.2.6.4.1 Spain Antiparasitic Market by Drug Class
10.2.6.4.2 Spain Antiparasitic Market by Disease Indication
10.2.6.4.3 Spain Antiparasitic Market by Distribution Channel
10.2.6.5 United Kingdom Antiparasitic Market
10.2.6.5.1 United Kingdom Antiparasitic Market by Drug Class
10.2.6.5.2 United Kingdom Antiparasitic Market by Disease Indication
10.2.6.5.3 United Kingdom Antiparasitic Market by Distribution Channel
10.2.6.6 Rest of Europe Antiparasitic Market
10.2.6.6.1 Rest of Europe Antiparasitic Market by Drug Class
10.2.6.6.2 Rest of Europe Antiparasitic Market by Disease Indication
10.2.6.6.3 Rest of Europe Antiparasitic Market by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Antiparasitic Market Overview
10.3.2 Asia-Pacific Antiparasitic Market Forecasts and Analysis
10.3.3 Asia-Pacific Antiparasitic Market Forecasts and Analysis - By Drug Class
10.3.4 Asia-Pacific Antiparasitic Market Forecasts and Analysis - By Disease Indication
10.3.5 Asia-Pacific Antiparasitic Market Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Antiparasitic Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Antiparasitic Market
10.3.6.1.1 Australia Antiparasitic Market by Drug Class
10.3.6.1.2 Australia Antiparasitic Market by Disease Indication
10.3.6.1.3 Australia Antiparasitic Market by Distribution Channel
10.3.6.2 China Antiparasitic Market
10.3.6.2.1 China Antiparasitic Market by Drug Class
10.3.6.2.2 China Antiparasitic Market by Disease Indication
10.3.6.2.3 China Antiparasitic Market by Distribution Channel
10.3.6.3 India Antiparasitic Market
10.3.6.3.1 India Antiparasitic Market by Drug Class
10.3.6.3.2 India Antiparasitic Market by Disease Indication
10.3.6.3.3 India Antiparasitic Market by Distribution Channel
10.3.6.4 Japan Antiparasitic Market
10.3.6.4.1 Japan Antiparasitic Market by Drug Class
10.3.6.4.2 Japan Antiparasitic Market by Disease Indication
10.3.6.4.3 Japan Antiparasitic Market by Distribution Channel
10.3.6.5 South Korea Antiparasitic Market
10.3.6.5.1 South Korea Antiparasitic Market by Drug Class
10.3.6.5.2 South Korea Antiparasitic Market by Disease Indication
10.3.6.5.3 South Korea Antiparasitic Market by Distribution Channel
10.3.6.6 Rest of Asia-Pacific Antiparasitic Market
10.3.6.6.1 Rest of Asia-Pacific Antiparasitic Market by Drug Class
10.3.6.6.2 Rest of Asia-Pacific Antiparasitic Market by Disease Indication
10.3.6.6.3 Rest of Asia-Pacific Antiparasitic Market by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Antiparasitic Market Overview
10.4.2 Middle East and Africa Antiparasitic Market Forecasts and Analysis
10.4.3 Middle East and Africa Antiparasitic Market Forecasts and Analysis - By Drug Class
10.4.4 Middle East and Africa Antiparasitic Market Forecasts and Analysis - By Disease Indication
10.4.5 Middle East and Africa Antiparasitic Market Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Antiparasitic Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Antiparasitic Market
10.4.6.1.1 South Africa Antiparasitic Market by Drug Class
10.4.6.1.2 South Africa Antiparasitic Market by Disease Indication
10.4.6.1.3 South Africa Antiparasitic Market by Distribution Channel
10.4.6.2 Saudi Arabia Antiparasitic Market
10.4.6.2.1 Saudi Arabia Antiparasitic Market by Drug Class
10.4.6.2.2 Saudi Arabia Antiparasitic Market by Disease Indication
10.4.6.2.3 Saudi Arabia Antiparasitic Market by Distribution Channel
10.4.6.3 U.A.E Antiparasitic Market
10.4.6.3.1 U.A.E Antiparasitic Market by Drug Class
10.4.6.3.2 U.A.E Antiparasitic Market by Disease Indication
10.4.6.3.3 U.A.E Antiparasitic Market by Distribution Channel
10.4.6.4 Rest of Middle East and Africa Antiparasitic Market
10.4.6.4.1 Rest of Middle East and Africa Antiparasitic Market by Drug Class
10.4.6.4.2 Rest of Middle East and Africa Antiparasitic Market by Disease Indication
10.4.6.4.3 Rest of Middle East and Africa Antiparasitic Market by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Antiparasitic Market Overview
10.5.2 South and Central America Antiparasitic Market Forecasts and Analysis
10.5.3 South and Central America Antiparasitic Market Forecasts and Analysis - By Drug Class
10.5.4 South and Central America Antiparasitic Market Forecasts and Analysis - By Disease Indication
10.5.5 South and Central America Antiparasitic Market Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Antiparasitic Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Antiparasitic Market
10.5.6.1.1 Brazil Antiparasitic Market by Drug Class
10.5.6.1.2 Brazil Antiparasitic Market by Disease Indication
10.5.6.1.3 Brazil Antiparasitic Market by Distribution Channel
10.5.6.2 Argentina Antiparasitic Market
10.5.6.2.1 Argentina Antiparasitic Market by Drug Class
10.5.6.2.2 Argentina Antiparasitic Market by Disease Indication
10.5.6.2.3 Argentina Antiparasitic Market by Distribution Channel
10.5.6.3 Rest of South and Central America Antiparasitic Market
10.5.6.3.1 Rest of South and Central America Antiparasitic Market by Drug Class
10.5.6.3.2 Rest of South and Central America Antiparasitic Market by Disease Indication
10.5.6.3.3 Rest of South and Central America Antiparasitic Market by Distribution Channel
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. ANTIPARASITIC MARKET, KEY COMPANY PROFILES
12.1. IPCA LABORATORIES LTD.
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. ZYDUS CADILA
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. MERCK KGAA
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. PFIZER
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. GLAXOSMITHKLINE PLC.
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. CIPLA LTD
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. RANBAXY LABORATORIES
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. NOVARTIS AG
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. ALVIZIA HEALTH CARE
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. BAYER AG
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
12.11. ROCHE INC
12.11.1. Key Facts
12.11.2. Business Description
12.11.3. Products and Services
12.11.4. Financial Overview
12.11.5. SWOT Analysis
12.11.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1. Ipca Laboratories Ltd.
2. Zydus Cadila
3. Merck KGaA
4. Pfizer
5. GlaxoSmithKline Plc.
6. Cipla Ltd
7. Ranbaxy Laboratories
8. Novartis AG
9. Alvizia Health Care
10. Bayer AG
11. Roche Inc
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For